原I是治疗瘤的有效治疗标
Yehyeong Lee1,2, Yonghyo Kim1, Chankyoung Lee1,2
1Data Convergence Drug Research Center, Therapeutics & Biotechnology Division, Korea Research Institute of Chemical Technology (KRICT).
Anti-cancer drugs
|November 3, 2025
概括
在小鼠模型中,Halofuginone hydrobromide (HH) 有效地抑制了desmoid瘤的生长. 这种原I向化合物也显示出对结直肠癌的承诺,这表明了新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 德斯莫体瘤 (侵略性纤维素瘤) 是一种具有局部侵袭特征的结缔组织瘤.
- 目前对desmoid瘤的治疗方法有限,其潜在的分子机制仍然不清楚.
- 在desmoid瘤中观察到Wnt通路组件和Trp53的频繁突变.
研究的目的:
- 为了研究治疗瘤的新疗法策略.
- 为了阐明desmoid瘤发展的分子机制.
- 为了识别有效的抗癌药物,准瘤.
主要方法:
- 开发了模拟desmoid瘤突变的小鼠模型 (Apc1638N/+, Apc1638N/+/Trp53-/-).
- 从这些小鼠模型中建立了主要的desmoid瘤细胞.
- 选了3120种FDA批准的化合物,以确定潜在的治疗剂.
主要成果:
- 鉴定了Halofuginone hydrobromide (HH),一种原I抑制剂,作为一种强大的抑制器的desmoid瘤细胞生长.
- HH在Apc1638N/+和Apc1638N/+/Trp53-/-的desmoid瘤细胞上表现出显著的抗癌作用.
- 此外,HH对结直肠癌细胞和肠道瘤有机体也表现出有效性.
结论:
- 向 I 型原是一种有前途的治疗策略,用于瘤.
- 哈洛基酸显示出作为治疗质瘤和结直肠癌的潜力.
- 对于这些恶性瘤,进一步研究原I作为治疗点是有必要的.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
The Tumor Microenvironment
7.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K
Fibril-associated Collagen
3.2K
Fibril-associated collagens are a type of collagens present in the extracellular matrix with interrupted triple helices or FACIT (Fibril-associated collagens interrupted triple-helices). FACIT help connect and attach the collagen fibrils with each other as well as with other proteins of the extracellular matrix.
For example, the type II collagen fibrils in cartilage have covalently bound type IX fibril-associated collagens at regular intervals. Other types of fibril-associated collagens are...
For example, the type II collagen fibrils in cartilage have covalently bound type IX fibril-associated collagens at regular intervals. Other types of fibril-associated collagens are...
3.2K
Collagens are the Major Structural Proteins of ECM
5.6K
Three main types of fibers are secreted by fibroblasts: collagen fibers, elastic fibers, and reticular fibers. Collagen fiber is made from fibrous protein subunits linked together to form a long, straight fiber. Collagen fibers, while flexible, have great tensile strength, resist stretching, and give ligaments and tendons their characteristic resilience and strength. These fibers hold connective tissues together, even during the body's movement.
Connective tissue proper includes loose...
Connective tissue proper includes loose...
5.6K
Role of Matrix Metalloproteases in Degradation of ECM
3.2K
Matrix metalloproteases (MMPs) are enzymes involved in the hydrolysis of proteins and glycoproteins of the extracellular matrix. MMPs are essential for the migration and proliferation of cells through the dense matrix network, throughout embryonic development, and throughout morphogenesis. The first MMP activity discovered was a collagenase in a tadpole's tail undergoing metamorphosis. The active collagen deposition and modifications lead to the morphogenesis of tadpoles into the adult...
3.2K


